The identity of other epigenetic factors that become dysregulated in EGFR/TP53/RB1 mutant lung cancers and their effects on mutant EGFR lung cancer lineage plasticity and therapeutic resistance is an area of active research that may yield additional therapeutic targets. This evidence concerns the gene TP53 and lung carcinoma.